Clique no nome do convidado e confira o minicurrículo:

Convidados Internacionais

Dr. McCall received his MD from the Medical College of Wisconsin and his PhD in Neural & Endocrine Regulation from the Massachusetts Institute of Technology. His clinical training was at the Boston University Medical Center where he did his residency in Internal Medicine, his Endocrinology fellowship and was Chief Medical Resident. At the University of Virginia he was the James M. Moss Professor of Diabetes in Internal Medicine (2001-2017), the Director of the Diabetes Clinical Services at UVA Health System, and the Medical Director of the Virginia Center for Diabetes Professional Education and the Director of the Inpatient Glucose Management Program. He was Vice-President for Clinical Science for the Endocrine Society 2015 to 2018. His research early focused on how diabetes and hypoglycemia affect the central nervous system. He worked with UVA colleagues on computer controlled insulin infusions for insulin pumps as an “artificial pancreas” therapy for type 1 diabetes at the Center for Diabetes Technology. For studies on hypoglycemia defenses, he worked with Dr. Leon Farhy on pancreatic network control of glucagon counter-regulation. He has had NIH funding for basic scientific work on understanding and reversing defective glucagon counterregulation in type 1 diabetes, for computer algorithms for glycemic control of inpatients undergoing cardiovascular surgery. He also has NIH funding with Dr. Daniel Cox for studies of use of monitoring and counseling on diet and exercise for glycemic control and with Dr. Jennifer Lobo for disparities for diabetes complications screening in rural areas, and with Dr. Sue Brown for examining immunity related abnormalities of Glucagon, amylin and zonulin in first degree relatives of those with type 1 diabetes. His clinical work has focused on diabetes complications and their prevention. He has published on disparities in prevention of complications of diabetes in rural areas. He established a Diabetes Cardiovascular Clinic program in 2002 with Cardiology and more recently Hepatology, which continues to deliver collaborative care for patients with diabetes and cardiometabolic risk. He currently works both at UVA in the Endocrine Division and at Cornell University as a Professor of Nutritional Sciences.

Prof. Diego Ferone, MD, PhD, born in Capri, Italy, February 11th 1962

Diego Ferone is Professor of Endocrinology at the Department of Internal Medicine & Medical Specialties, section of Endocrinology, at the University of Genova, senior member and General Secretary of the Italian Endocrine Society (where he also served as Treasurer), past-secretary of the Italian Society of Andrology and Sexual Medicine, member of the Advisory Board of the European Neuroendocrine Tumor Society and of several Editorial Boards, past member of the ExCo of the European Neuroendocrine Association, Associate Editor for the Journal of Endocrinological Investigation and past associate editor for Clinical Endocrinology.
Diego Ferone, after the degree in Medicine and the postgraduate degree in Endocrinology and Metabolic Diseases at the “Federico II” University of Naples, received the PhD degree in Neuroendocrinology in Rotterdam at the Erasmus University, where he spent more than 4 years in the laboratory of Steven Lamberts and Leo Hofland. He has been awarded by the Italian Society of Endocrinology as best young investigator in 1999, best senior scientist (career award) in 2011, and he also received the an award as best Italian researcher in the field of Neuroendocrine Tumors and MEN in 2010. Dr. Ferone has been constantly involved in studies on the physiopathology and treatment of pituitary and neuroendocrine tumors, physiopathology of somatostatin and dopamine receptors in the immune and neuroendocrine systems, medical therapy of acromegaly, Cushing disease, neuroendocrine tumors and hypopituitarism, and is author of more than 250 peer reviewed articles. Moreover, he presented more than 500 lectures in international and national meetings, and is author of 30 chapters of book (total impact factor over 530; h-index 44).
He has been among the organizers of the XXXI Congress of Italian Endocrine Society (Genova 2005), of the First Italian Endocrine Oncology Workshop (Udine 2009) and of the First National Congress of Endocrine Oncology: from bench to bedside (Rome 2011), of the Master Up-to Date in Neuro-Onco-Endocrinology (2010 Genova); Member of the POC of the 2010 and 2014 ENEA Meetings (Liege and Sofia) and of the 12th International Workshop on Multiple Endocrine Neoplasia (Gubbio 2010), President of the POC for the 2016 ENEA Meeting (Milan, Italy).

Jens Otto Jørgensen is Consultant and Professor of Endocrinology in the Medical Department MEA (Endocrinology and Diabetes) at Aarhus University Hospital, Aarhus, Denmark.
Professor Jørgensen’s research mainly focusses on growth hormone, substrate metabolism and pituitary endocrinology, and he has authored 500 publications, with more than 12,000 citations and an H-index of 69. He is a member of the Danish Endocrine Society, for which he spent 4 years on the Council, the Pituitary Society, the Endocrine Society, and was a Council member of the European Neuroendocrine Association. He is also a founding member and current treasurer of the Growth Hormone Research Society (GRS), and since 2017 he has been the clinical Focus Area lead for the European Society of Endocrinology Pituitary and Neuroendocrinology Focus Area.
Professor Jørgensen has been co-editor of GH and IGF Research, a former member of the Editorial Board of the European Journal of Endocrinology, and is currently a member of the Editorial Boards of Endocrine and Pituitary and a senior editor of Endocrine Connection.

Dr. Bilezikian, the Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons, Columbia University is Vice Chair of the Department of Medicine for International Education and Research and Chief, Emeritus, of the Division of Endocrinology. He is Director of the Metabolic Bone Diseases Program at Columbia University Medical Center. Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians & Surgeons. He completed four years of house staff training (internship, residency and Chief Residency) on the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the National Institutes of Health in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach. He belongs to a number of professional societies including the American Society of Bone and Mineral Research, of which he served as President (ASBMR), 1995-1996 and the International Society of Clinical Densitometry, of which he served as President, 1999-2001. He is a member of the Endocrine Society (ISCD), the American Federation for Clinical Research, the American Society for Clinical Investigation, the Association of American Physicians, the American Association of Clinical Endocrinologists, the American Society for Pharmacology and Experimental Therapeutics, and the American College of Endocrinology that has designated him Master. He served on the Board of Governors of the International Osteoporosis Foundation (1999-2015) and is a current member of its Committee of Scientific Advisors. He is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism and as Senior Associate Editor of the Journal of Bone and Mineral Research. He is Executive Advisory Editor of Bone Research. His books include Editor-in-Chief of The Parathyroids [1994, 2001, 2015], and co-editor of The Aging Skeleton (1999), Dynamics of Bone and Cartilage Metabolism (1999, 2006), Principles of Bone Biology (1996, 2002, 2008, 2018) and Osteoporosis in Men (2010). He is Editor-in-Chief of the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (2018). He has been on numerous panels, including serving as Chair of the NIH Consensus Development Panel on Optimal Calcium Intake (1994), Co-chair of the last three International Workshops on Primary Hyperparathyroidism (2002, 2008, 2013) and of the first International Workshops on Hypoparathyroidism (2015) and Controversies in Vitamin D (2017). He is a major national and international spokesperson for the field of metabolic bone diseases. Dr. Bilezikian's major research interests are related to the clinical investigation of metabolic bone diseases, particularly osteoporosis, primary hyperparathyroidism and hypoparathyroidism. He is the recipient of the Distinguished Physician Award of the Endocrine Society, the Frederic C. Bartter Award of the ASBMR for Excellence in Clinical Research, and the First Annual Global Leadership Award of the ISCD. In 2009, he received the Gideon A. Rodan Excellence in Mentorship Award from the ASBMR. He received the Laureate Distinguished Educator Award of the Endocrine Society in 2014. In 2014, he was made honorary member of the Brazilian Society of Endocrinology and Metabolism. In 2015, he received the Oscar Gluck Humanitarian Award of the ISCD and the Inaugural Global Educator of the Year Award from McMaster University in Canada. In 2017, was named Honorary Member of the Russian Osteoporosis Association. Dr. Bilezikian has received Lifetime Achievement and Recognition Awards of the California and Boston Armenian American Medical Societies and the Armenian American Health Professionals Organization (AAHPO). In 2017, he received the Doctor Honoris Causa Award from the Carol Davila School of Medicine in Bucharest, Romania and from the University of Pisa, in Pisa, Italy. He will receive the Distinguished Physician Award of the American Association of Clinical Endocrinologists in 2018. He will also receive the Ellis Island Congressional Medal of Honor in 2018.
Over 800 publications speak to his active original investigative initiatives as well as his authorship of many reference sources of endocrinology and metabolic bone diseases.

Lynnette Nieman, MD is a Senior Investigator at the NIH Clinical Research Center and head of the Endocrine Consult service. She also directs the Office of Human Subjects Research Protections for intramural NIH. Dr. Nieman is an active clinical investigator, with eleven active protocols and special expertise in disorders of hypercortisolism. She has authored more than 250 publications and sponsored three investigational new drug applications, one of which was licensed in the US and Europe.
Dr. Nieman served as an associate editor for the Journal of Clinical Endocrinology and Metabolism and is a past member of the Endocrinology and Metabolism subcommittee of the American Board of Internal Medicine. She has received the NIH Director’s Award, NIH Clinical Teacher of the Year Award and the Endocrine Society’s Distinguished Physician award. She has provided Congressional testimony. Dr. Nieman is currently the Immediate Past President of the Endocrine Society and a past Vice President for Clinical Science of the Endocrine Society. She Chaired the Endocrine Society’s 2012 annual meeting, and has served on the Strategic Planning Committee and the Committee on Governance Affairs.

Michael S. Irwig, MD, F.A.C.E., is board-certified in Endocrinology & Metabolism and is an associate professor of Medicine at The George Washington University School of Medicine & Health Sciences. He also is an adjunct associate professor of Medicine at Georgetown University School of Medicine Dr. Irwig is a general endocrinologist with a particular interest and expertise in androgens and transgender care. His research has focused on men with persistent sexual and non-sexual side effects of finasteride (Propecia), transgender health and men with borderline testosterone levels. He has over 30 peer-reviewed publications appearing in multiple journals including Current Opinion in Endocrinology, Diabetes and Obesity, Diabetic Medicine, Endocrine Practice, JAMA Dermatology, Journal of Clinical Endocrinology and Metabolism, Journal of Clinical Psychiatry, Journal of Sexual Medicine, Lancet Diabetes & Endocrinology and Nature Reviews Urology. His research findings have been featured in many national and international mainstream publications and broadcast outlets including: The Today Show, NBC Nightly News, ABC World News, CBS News,, CNN, Men’s Health Magazine, Men’s Journal and The Philadelphia Inquirer. Dr. Irwig has presented over 100 lectures at hospitals and medical schools across the world on several topics including male hypogonadism and transgender health. He also serves as a reviewer for over 36 peer-reviewed medical journals. He is the past president of the mid-Atlantic chapter of the American Association of Clinical Endocrinologists (AACE). He serves on national committees for AACE as well as the Endocrine Society, including the Endocrine Self-Assessment Committee (ESAP). Dr. Irwig received his M.D. degree from Cornell University and completed his residency in internal medicine at the University of Virginia. He was a senior fellow in endocrinology, metabolism, and nutrition at the University of Washington in Seattle. Dr. Irwig does not accept any funding from pharmaceutical companies.

Mirjam Christ-Crain is full Professor of Endocrinology, Diabetes and Metabolism at the University of Basel and the University Hospital of Basel, Switzerland. She studied medicine in Basel and Vienna and did her MD in the year 2000 at the University of Basel and her PhD 2007 at the University of London followed by her habilitation at the University of Basel in 2007. From 2009 to 2015 she had a research professorship of the Swiss National Science Foundation. Her special research interest is on one side stress hormones in inflammation and metabolic disorders and on the other side water and salt homeostasis. She authored and co-authored more than 200 publications and received several awards for her research. Since 2013 she is Deputy Chief at the Clinic for Endocrinology, University Hospital Basel and since 2014 she is Head of the Department of Clinical Research at the University of Basel.

Professor Peter Rossing MD DMSc, Head of Complications Research, Chief Physician, Steno Diabetes Center Copenhagen, Denmark Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes. Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis. He is coordinator of the EU FP7 project PRIORITY aiming to test if urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy. He has co-authored >300 papers and his h-index is 57. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry

Raúl M. Luque [1973; BS in Biology [University of Cordoba (UCO), 1997] and PhD in Sciences (UCO; 2003)] is Associate Professor at the University of Cordoba (UCO) and Principal Investigator (PI) of the “Hormones and Cancer” research group at the Maimonides Biomedical Research Institute of Cordoba (IMIBIC). Dr. Luque started his scientific career with a highly competitive FPU grant and continued his Postdoctoral training with a fellowship from the Junta de Andalucía and, then, as Research Assistant Professor at the University of Illinois at Chicago (USA; 2003-2007). In 2007, Dr. Luque was reincorporated at the UCO as Ramón y Cajal Researcher, establishing his own research line as PI of the “Hormones and Cancer” group. His expertise lies in Endocrinology, Metabolism and Cancer, with special attention to the neuroendocrine regulation of the GH-IGFI axis (i.e. study of the cellular and molecular events responsible for the proper functioning of the hypothalamic-pituitary unit and its interrelationship with metabolism and cancer), as well as the characterization of novel classical and novel metabolic signals involved in the integrated control of different endocrine tissues/organs (i.e. pituitary, hypothalamus, liver, etc.), and their mechanisms of action. During the last years, Dr. Luque has obtained research funds (as PI) for several projects from public (FIS, Merck-Serono, etc.) and private (IPSEN; Novartis) sources and actively collaborate in national (CIBERobn, PIE14-00005...), and international (UE, NIH) actions, demonstrating his leadership capacity. In total, Dr. Luque has published over 125 articles in international peer-reviewed journals over the last 15 years (Pubmed database as “Luque RM” or “Luque R”; from April 2002 to November 2017), including a significant number of research papers and invited reviews in authoritative, highly-ranked journals of the Endocrinology, Diabetes and Metabolism field (most of them in Q1 in these fields and in a high percentage as first or corresponding author). The journals of publication of Dr. Luque´s work have included Oncogene, Cancer Letters, Journal of Clinical Endocrinology and Metabolism, Endocrinology, FASEB J, J Cell Mol Med, etc. The total number of citations of Dr. Luque’s work is presently >2800, with an H-index of 32. In addition, he has participated as invited speaker in numerous international meetings, and serves or has served as member of the Editorial Board (acting as Editor in Chief, Associate Editor or member of the reviewer panel) of prestigious journals of the field, such as the Journal of Clinical Endocrinology and Metabolism, Journal of Endocrinology and Journal of Molecular Endocrinology, Journal of Endocrinological Investigation, Endocrine, Frontiers in Systems and Translational Endocrinology, etc. Dr. Luque is also the Head of the “Hormone and Cancer” group at the Maimonides Biomedical Research Institute (IMIBIC)/University of Cordoba and, he has been a highly implicated promoter of the Spanish and European Society of Endocrinology and Nutrition (for instance, he is the current Basic Co-chair of the next ECE that will be held in Barcelona in 2018), of the CIBERobn (National Spanish Research Network for Obesity and Nutrition) and other Societies [ENEA, (i.e. he was member of the POC of the ENEA meeting 2016 in Milan, Italy), Endo-Society, etc.]. Dr. Luque has several registered patents and is member of different panels of project evaluation (ANEP, FIS, and agencies from France, Italy and Argentina). Dr. Luque has obtained more than 20 scientific awards (SAEN, SEEN, ENEA, ESE, EndoSociety, etc.) and has been involved in different administrative activities [Academic Director of the Master on Traslational Biomedical Reseach of UCO, Coordinator of the Animal Research Service at the IMIBIC, member of the infrastructure committee of the IMIBIC and of the Biomedical Ethic Committee of UCO, member of the SAEDYN advisory board, etc]. Finally, Raul´s teaching duties have been evaluated as excellent (95/100) by the General System of Educational Evaluation (ANECA).

Dr. Susan J. Mandel, MD, MPH is a Professor of Medicine and Radiology and Associate Chief of the Division of Endocrinology, Diabetes and Metabolism at the University of Pennsylvania where she directs the Endocrine fellowship. After medical school at the College of Physicians and Surgeons, she completed a medical residency at Columbia Presbyterian Medical Center and a fellowship in endocrinology at the Brigham and Women‘s. At Penn, she oversees a clinical practice with over 23,000 annual visits. Her clinical practice focuses on patients with thyroid neoplasia and she has been recognized for clinical excellence with the Penn Duhring Clinical Specialist award. Her research interests include the use of sonography in the evaluation of patients with thyroid nodules and cancer, and thyroid disease during pregnancy. Dr. Mandel has served on the writing groups for the American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and the Management of Thyroid Disease during Pregnancy. She also initiated and directs the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society‘s Distinguished Educator Award and the H. Jack Baskin Educator Award of the American Association of Clinical Endocrinologists. She is the current President of the Endocrine Society, a past President of the Association of Program Directors in Endocrinology, Diabetes, and Metabolism, and a past Endocrine Society Council member and Vice President Physician-in-Practice.

Convidados Internacionais

local do evento


Comportando um público de aproximadamente 45 mil pessoas, o Expominas é utilizado para grandes eventos musicais, culturais e empreendedores da capital mineira, em ambientes internos e externos. Localizado na Avenida Amazonas, o espaço possui um pavilhão com 5.184m², a arena multiuso, com 2.630m² e uma passarela de ligação com 1.076m², no Parque da Gameleira, região oeste de Belo Horizonte. Além disso, é o único Centro de Convenções e Eventos da América Latina ligado diretamente a uma estação de metrô: a Estação Gameleira, permitindo que o público esteja no centro da cidade em alguns minutos.

Avenida Amazonas, 6200 - Gameleira - Belo Horizonte/MG
Telefone: (31) 3334-5145